Medication use among all patients with juvenile idiopathic arthritis (n = 2748).
| Medication | Medication Users, n (% of total) |
|---|---|
| Any nonbiologic DMARD | 2023 (74) |
| Methotrexate | 1939 (71) |
| Sulfasalazine | 228 (8) |
| Leflunomide | 96 (3) |
| Any biologic DMARD | 1246 (45) |
| TNF inhibitors | 1196 (44) |
| Etanercept | 972 (35) |
| Adalimumab | 378 (14) |
| Infliximab | 220 (8) |
| Golimumab | 17 (1) |
| Certolizumab | 8 (< 1) |
| IL-1 inhibitors | 111 (4) |
| Anakinra | 106 (4) |
| Rilonacept | 13 (< 1) |
| Canakinumab | 7 (< 1) |
| Abatacept | 77 (3) |
| Rituximab | 19 (1) |
| Tocilizumab | 16 (1) |
| Intraarticular glucocorticoid | 1258 (46) |
| Systemic glucocorticoid | 1041 (38) |
| Oral glucocorticoid | 1031 (38) |
| Intravenous pulse glucocorticoid | 132 (5) |
| Current daily NSAID | 1393 (51) |
DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor-α; IL-1: interleukin 1; NSAID: nonsteroidal antiinflammatory drug.